Here is a striking case of a stock poised for profitable growth. The company meets a critical health care need with an impressive competitive edge. These are defining conditions for a business to do well. Stock investment and business management students can use this company as a live case of unearthing imminent new stock value.
The management has executed a master stroke in appointing an established player in an allied field as an exclusive national distributor for the United States. The new distributor makes valves for hearts, while the company under review is involved with small and precise catheters to restore normal heart beats. The two brand lines do not compete with each other, but the surgeons who use them are the same.
US regulators have approved the company’s major brand for use in cardiac procedures. The company also has a world-wide presence in its specialized field of surgery. It is recognized for expertise in making devices that allow doctors to operate quicker with lesser injuries, which allows patients to heal and get well sooner. The company’s Scientific Advisory Board includes a member who is a leading authority in treating heart beat irregularities.
Cardiac pathologies are on the rise; many patients do not respond adequately to drugs alone, and need surgical interventions to avoid such serious conditions as strokes. The company has begun to participate in key scientific events, and should be on the verge of a major commercial entry in to the US market for cardiac fibrillation catheters.
Let us hear your thoughts below: